ストックスクリーナーアプリを入手
21.65
1.88%
0.40
アフターアワーズ：
21.80
0.15
+0.69%
前日終値:
$21.25
開ける：
$21.45
24時間の取引高:
1.25M
Relative Volume:
1.00
時価総額：
$1.39B
収益：
$193.35M
当期純損益:
$-177.58M
株価収益率:
-8.8367
EPS:
-2.45
ネットキャッシュフロー:
$-172.43M
1週間 パフォーマンス:
-0.28%
1か月 パフォーマンス:
+3.69%
6か月 パフォーマンス:
+13.95%
1年 パフォーマンス:
-6.56%
1日の値動き範囲:
$21.41
$22.50
1週間の範囲:
$20.15
$22.50
52週間の値動き範囲:
$16.60
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
SDGR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
21.65 | 1.59B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
276.46 | 46.47B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
60.65 | 10.11B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
100.12 | 8.65B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
61.60 | 11.88B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
37.06 | 6.56B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-07-02 | 開始されました | Leerink Partners | Outperform |
| 2023-12-05 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | 再開されました | Piper Sandler | Overweight |
| 2022-12-19 | 開始されました | Goldman | Neutral |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2021-11-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-10-13 | 開始されました | Berenberg | Buy |
| 2021-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | 開始されました | Craig Hallum | Buy |
| 2020-11-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-10-12 | アップグレード | Jefferies | Hold → Buy |
| 2020-03-02 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-02 | 開始されました | Jefferies | Hold |
| 2020-03-02 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Schrodinger Inc (SDGR) 最新ニュース
Schrodinger stock maintains Buy rating at Citi on Ajax collaboration By Investing.com - Investing.com Canada
Ajax Therapeutics and Schrödinger expand JAK inhibitor collaboration - Investing.com
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target - Stock Titan
What makes Schrödinger Inc. stock price move sharplyMoney Making Low Risk Plans - beatles.ru
Morgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock - MSN
BMO Capital Remains a Buy on Schrodinger (SDGR) - The Globe and Mail
(SDGR) On The My Stocks Page - news.stocktradersdaily.com
Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505 - MSN
Schrodinger stock rating assumed by Morgan Stanley at Equalweight - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc.SDGR - WV News
Schrödinger Demonstrates Corporate Sustainability Progress in 2024 Report - ReportAlert
Schrödinger gets Fast Track status for SGR-1505 - MSN
Schrödinger (SDGR) Gains FDA Fast Track for MALT1 Inhibitor - GuruFocus
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia | SDGR Stock News - GuruFocus
Schrödinger’s MALT1 inhibitor receives FDA fast track designation - Investing.com
Schrodinger Announces Board Elections and Approvals - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger - Bluefield Daily Telegraph
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | PRN_FinancialWrapper | PR Newswire - FinancialContent
Where are the Opportunities in (SDGR) - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, ... - Eagle-Tribune
Harbor Capital Advisors Inc. Grows Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger slides after early-stage trial data for cancer therapy - MSN
Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results - Seeking Alpha
Schrödinger (SDGR) Shares Dip After Initial Phase 1 Trial Data - GuruFocus
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data fo - GuruFocus
Schrodinger Reports 22% Response Rate in Phase 1 Trial of SGR-1505 for B-Cell Cancers; Shares Fall - MarketScreener
Schrödinger stock slides on cancer trial data (SDGR:NASDAQ) - Seeking Alpha
Transcript : Schrödinger, Inc.Special Call - MarketScreener
Schrodinger (SDGR) Reports Promising Phase 1 Results of SGR-1505 | SDGR Stock News - GuruFocus
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress - Eagle-Tribune
Day 9 of Gains Streak for Schrodinger Stock with 24% Return (vs. 38% YTD) [6/11/2025] - Trefis
Schrodinger Inc (SDGR) Trading 5.17% Higher on Jun 11 - GuruFocus
California State Teachers Retirement System Reduces Holdings in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of “Buy” from Analysts - Defense World
Comparing Schrödinger (NASDAQ:SDGR) & Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
Schrödinger's Stock in a Quantum State: Fraud Probe and Leadership Shake-Up Cloud the Outlook - AInvest
Schrodinger Inc (SDGR) Trading 4.34% Higher on Jun 6 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Schrodinger Shows Rising Price Performance With Jump To 82 RS Rating - Investor's Business Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect - ACCESS Newswire
Kalkine NASDAQ 100 Top Stocks Leading Technology Giants Driving Market Growth - Kalkine Media
24,500 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by Two Sigma Advisers LP - Defense World
Bank of America Corp DE Reduces Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrodinger at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Schrodinger at Jefferies Conference: Strategic Growth and Challenges - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Schrodinger Inc (SDGR) 財務データ
収益
当期純利益
現金流量
EPS
Schrodinger Inc (SDGR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
1.25%
0.96%
大文字化:
|
ボリューム (24 時間):